Remove Disease Remove Organic Chemistry Remove Treatment
article thumbnail

Antibody Drug Conjugates: windows of opportunity

Drug Target Review

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. ADCs have the potential to redress the poor balance between safety and efficacy seen with traditional cancer treatment options.

article thumbnail

Bavtavirine

New Drug Approvals

Institute of Organic Chemistry and Biochemistry of the AS CR, v.v.i. Bavtavirine is part of highly active antitiretroviral therapy (HAART) treatment regimen. Bavtavirine can be used for HIV disease research. Bavtavirine is a potent non-nucleoside reverse transcriptase inhibitors (NNRTIs).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Welcome to new Director David Hulcoop

The Open Targets Blog

After completing my PhD in organic chemistry at the University of Cambridge, I went to Canada as a Leverhulme Trust postdoctoral fellow. It’s a multi-dimensional, cross-disciplinary problem, requiring an understanding of genetics, of disease biology, and of drug discovery factors. I’m a chemist by training.

article thumbnail

How to Get Drugs Into the Brain

Drug Hunter

Obtaining adequate drug exposure in the brain is key to treating CNS diseases effectively. Prodrugs Remain in “Proof-of-Concept” Stages Prodrug strategies for CNS deliver have also been applied with varying success , with the most famous example being L-Dopa for Parkinson’s disease. Figure 18.

Drugs 206
article thumbnail

Marquis Who’s Who Honors David R. Elmaleh, PhD, with Inclusion in Who’s Who in the World

The Pharma Data

Elmaleh’s research has yielded compounds with potential in oncology, heart disease and neurodegenerative conditions, BOSTON, MA, October 23, 2020 /24-7PressRelease/ — Marquis Who’s Who, the world’s premier publisher of biographical profiles, is proud to honor David.

article thumbnail

Marquis Who’s Who Honors James D. McChesney, PhD, with Inclusion in Who’s Who in the World

The Pharma Data

McChesney is the founder and chief executive officer of Cloaked Therapeutics and Arbor Therapeutics, through which he has drawn on more than five decades of research in natural products chemistry to identify and develop novel cancer treatments.

article thumbnail

Women in Stem with Dr Rachel Lagiakos

Drug Target Review

Coupling my desire to be a scientist with my keen sense of adventure, I moved to Alaska out of high school to begin my undergraduate studies in chemistry, applying myself to my STEM classes whilst also climbing mountains and chasing Northern Lights.